Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide for Lymphopenia in COVID-19
NCT04910230Completed
- Start
- Mar 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nicotinamide in coronavirus disease 2019 (COVID-19) and lymphopenia. Primary endpoint: Absolute Lymphocyte Count Change at 48 hours. Started Mar 2020; status: completed.
02
Drugs
nicotinamide
03
Conditions
coronavirus disease 2019 (COVID-19)lymphopenia
Beyond the preview
Go deeper on NCT04910230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910230.